menu
    • menu

    Company profile for Actavis Inc

    NEW Drugs in Dev: 26
    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

    Virtual Booth

    Contact Supplier

    Sharp is a leader in commercial packaging, clinical services, and sterile manufacturing.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    As a CDMO, Mikart offers integrated CDMO services for Solid Dose & Non-sterile Liquid formulations.

    Virtual Booth

    Contact Supplier

    Trusted Global CDMO Partner Delivering End-to-End Pharma Manufacturing & Development Solutions.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    EXCIPIENTS

    REF. STANDARDS & IMPURITIES

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Actavis plc (NYSE: ACT) is a unique specialty pharmaceutical company focused on developing, manufacturing and commercializing high quality affordable generic and innovative branded pharmaceutical products for patients around the world. The Company has global headquarters in Dublin, Ireland and U.S. Administrative Headquarters in Parsippany, New Jersey, USA.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Actavis IncIreland Flag
    Country
    Country
    Ireland
    Address
    Address
    1 Grand Canal Square Docklands Dublin 2 Ireland
    Telephone
    Telephone
    353 214619040
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    http://www.actavis.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    RDD

    RDD

    Not Confirmed

    envelop Contact Supplier

    RDD

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Actavis’s Generics Rifaximin Receives Approval in US
    Actavis’s Generics Rifaximin Receives Approval in US

    19 Mar 2026

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208959

    FDA
    19 Mar 2026
    Share Share
    Class Action Over Generic Clobetasol And Clomipramine
    Class Action Over Generic Clobetasol And Clomipramine

    06 May 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/fine-kaplan-and-black-rpc-announce-class-action-lawsuits-on-behalf-of-those-who-paid-andor-reimbursed-for-generic-clobetasol-between-september-1-2014-and-december-31-2018-or-generic-clomipramine-between-august-1-2013-and--302446187.html

    PR NEWSWIRE
    06 May 2025
    Share Share
    Actavis to Slash 200 Workers as Teva’s Consolidation Efforts
    Actavis to Slash 200 Workers as Teva’s Consolidation Efforts

    08 Apr 2025

    // BIOSPACE

    https://www.biospace.com/actavis-to-slash-200-workers-as-part-of-teva-s-consolidation-efforts

    BIOSPACE
    08 Apr 2025
    Share Share
    Actavis`s Generics Methylnaltrexone Br. Receives Approval in US
    Actavis`s Generics Methylnaltrexone Br. Receives Approval in US

    26 Aug 2024

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208112

    FDA
    26 Aug 2024
    Share Share
    Actavis Lab's Generic Phentermine HCL;Topiramate Receives Approval in US
    Actavis Lab's Generic Phentermine HCL;Topiramate Receives Approval in US

    25 Jun 2024

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204982

    FDA
    25 Jun 2024
    Share Share
    Enforcement Report - Week of February 7, 2024
    Enforcement Report - Week of February 7, 2024

    07 Feb 2024

    // FDA

    https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-february-7-2024-67267.pdf

    FDA
    07 Feb 2024
    Share Share

    Drugs in Development

    read-more
    read-more
    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    LENZ and Lotus Sign License Deal for LNZ100 in Korea and Southeast Asia

    Details:

    Under the licensing agreement, Lotus will holds the rights of LNZ100 (Aceclidine HCl) in Korea, which is being evaluated for the treatment of Presbyopia.


    Lead Product(s): Aceclidine Hydrochloride,Brimonidine Tartrate

    Therapeutic Area: Ophthalmology Brand Name: Undisclosed

    Study Phase: Phase IIIProduct Type: Miscellaneous

    Recipient: LENZ Therapeutics

    Deal Size: $125.0 million Upfront Cash: Undisclosed

    Deal Type: Licensing Agreement May 09, 2025

    blank

    01

    Lotus Pharmaceutical

    Taiwan
    arrow
    RDD
    Not Confirmed

    Lotus Pharmaceutical

    Taiwan
    arrow
    RDD
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Aceclidine Hydrochloride,Brimonidine Tartrate

    Therapeutic Area : Ophthalmology

    Highest Development Status : Phase III

    Recipient : LENZ Therapeutics

    Deal Size : $125.0 million

    Deal Type : Licensing Agreement

    DEALS_DEV arrow-down

    LENZ and Lotus Sign License Deal for LNZ100 in Korea and Southeast Asia

    Details : Under the licensing agreement, Lotus will holds the rights of LNZ100 (Aceclidine HCl) in Korea, which is being evaluated for the treatment of Presbyopia.

    Product Name : Undisclosed

    Product Type : Miscellaneous

    Upfront Cash : Undisclosed

    May 09, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lotus Becomes Strategic Partner for the Commercialization of Biosimilar Ahzantive

    Details:

    Through the collaboration, Lotus will lead the commercialization of Ahzantive (Aflibercept) in the designated regions, a biosimilar candidate to Eylea.


    Lead Product(s): Aflibercept

    Therapeutic Area: Ophthalmology Brand Name: Ahzantive

    Study Phase: Approved FDFProduct Type: Protein

    Recipient: Klinge Pharma

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Licensing Agreement February 05, 2025

    blank

    02

    Lotus Pharmaceutical

    Taiwan
    arrow
    RDD
    Not Confirmed

    Lotus Pharmaceutical

    Taiwan
    arrow
    RDD
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Aflibercept

    Therapeutic Area : Ophthalmology

    Highest Development Status : Approved FDF

    Recipient : Klinge Pharma

    Deal Size : Undisclosed

    Deal Type : Licensing Agreement

    DEALS_DEV arrow-down

    Lotus Becomes Strategic Partner for the Commercialization of Biosimilar Ahzantive

    Details : Through the collaboration, Lotus will lead the commercialization of Ahzantive (Aflibercept) in the designated regions, a biosimilar candidate to Eylea.

    Product Name : Ahzantive

    Product Type : Protein

    Upfront Cash : Undisclosed

    February 05, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Corium and Lotus Pharmaceutical Enter into Exclusive License Agreement for Innovative Alzheimer's Disease Treatment ADLARITY® in Multiple Markets Acros...

    Details:

    Under the terms of the agreement, Lotus will have exclusive rights to commercialize Adlarity (donepezil transdermal system), an innovative Alzheimer’s dementia treatment, in the applicable territory and will be responsible for the regulatory approval process.


    Lead Product(s): Donepezil

    Therapeutic Area: Neurology Brand Name: Adlarity

    Study Phase: Approved FDFProduct Type: Miscellaneous

    Recipient: Corium

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Licensing Agreement August 10, 2023

    blank

    03

    Lotus Pharmaceutical

    Taiwan
    arrow
    RDD
    Not Confirmed

    Lotus Pharmaceutical

    Taiwan
    arrow
    RDD
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Donepezil

    Therapeutic Area : Neurology

    Highest Development Status : Approved FDF

    Recipient : Corium

    Deal Size : Undisclosed

    Deal Type : Licensing Agreement

    DEALS_DEV arrow-down

    Corium and Lotus Pharmaceutical Enter into Exclusive License Agreement for Innovative Alzheimer's ...

    Details : Under the terms of the agreement, Lotus will have exclusive rights to commercialize Adlarity (donepezil transdermal system), an innovative Alzheimer’s dementia treatment, in the applicable territory and will be responsible for the regulatory approval p...

    Product Name : Adlarity

    Product Type : Miscellaneous

    Upfront Cash : Undisclosed

    August 10, 2023

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Anti-BCMA Chimeric Antigen Receptor T Cells for Relapsed or Refractory Multiple Myeloma

    Details:

    Fludarabine is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Multiple Myeloma.


    Lead Product(s): Fludarabine Phosphate,Cyclophosphamide

    Therapeutic Area: Oncology Brand Name: Undisclosed

    Study Phase: Phase IProduct Type: Miscellaneous

    Sponsor: Thomas Martin, MD

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable October 13, 2022

    blank

    04

    Actavis Inc

    Ireland
    arrow
    RDD
    Not Confirmed

    Actavis Inc

    Ireland
    arrow
    RDD
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Fludarabine Phosphate,Cyclophosphamide

    Therapeutic Area : Oncology

    Highest Development Status : Phase I

    Partner/Sponsor/Collaborator : Thomas Martin, MD

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Anti-BCMA Chimeric Antigen Receptor T Cells for Relapsed or Refractory Multiple Myeloma

    Details : Fludarabine is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Multiple Myeloma.

    Product Name : Undisclosed

    Product Type : Miscellaneous

    Upfront Cash : Inapplicable

    October 13, 2022

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Evaluation of the Effects of Multiple Doses of Cebranopadol on the Electrical Activity of the Heart in Healthy Subjects

    Details:

    Cebranopadol is a Controlled Substance drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Long QT Syndrome.


    Lead Product(s): Cebranopadol

    Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Undisclosed

    Study Phase: Phase IProduct Type: Controlled Substance

    Recipient: Tris Pharma Inc

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable May 21, 2019

    blank

    05

    Forest Laboratories

    U.S.A
    arrow
    RDD
    Not Confirmed

    Forest Laboratories

    U.S.A
    arrow
    RDD
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Cebranopadol

    Therapeutic Area : Cardiology/Vascular Diseases

    Highest Development Status : Phase I

    Recipient : Tris Pharma Inc

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Evaluation of the Effects of Multiple Doses of Cebranopadol on the Electrical Activity of the Hear...

    Details : Cebranopadol is a Controlled Substance drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Long QT Syndrome.

    Product Name : Undisclosed

    Product Type : Controlled Substance

    Upfront Cash : Inapplicable

    May 21, 2019

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    A Clinical Endpoint Bioequivalence Study of "Oxymetazoline Hydrochloride Cream"

    Details:

    Oxymetazoline HCl is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Rosacea.


    Lead Product(s): Oxymetazoline Hydrochloride

    Therapeutic Area: Dermatology Brand Name: Undisclosed

    Study Phase: Phase IIIProduct Type: Miscellaneous

    Sponsor: Teva Pharmaceutical Industries

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable May 17, 2019

    blank

    06

    Actavis Inc

    Ireland
    arrow
    RDD
    Not Confirmed

    Actavis Inc

    Ireland
    arrow
    RDD
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Oxymetazoline Hydrochloride

    Therapeutic Area : Dermatology

    Highest Development Status : Phase III

    Partner/Sponsor/Collaborator : Teva Pharmaceutical Industries

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    A Clinical Endpoint Bioequivalence Study of "Oxymetazoline Hydrochloride Cream"

    Details : Oxymetazoline HCl is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Rosacea.

    Product Name : Undisclosed

    Product Type : Miscellaneous

    Upfront Cash : Inapplicable

    May 17, 2019

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    A Clinical Study to Evaluate the Effect of Renal Impairment on the Pharmacokinetics of Cebranopadol

    Details:

    Cebranopadol is a Controlled Substance drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.


    Lead Product(s): Cebranopadol

    Therapeutic Area: Undisclosed Brand Name: Undisclosed

    Study Phase: Phase IProduct Type: Controlled Substance

    Recipient: Tris Pharma Inc

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable March 20, 2019

    blank

    07

    Forest Laboratories

    U.S.A
    arrow
    RDD
    Not Confirmed

    Forest Laboratories

    U.S.A
    arrow
    RDD
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Cebranopadol

    Therapeutic Area : Undisclosed

    Highest Development Status : Phase I

    Recipient : Tris Pharma Inc

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    A Clinical Study to Evaluate the Effect of Renal Impairment on the Pharmacokinetics of Cebranopado...

    Details : Cebranopadol is a Controlled Substance drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

    Product Name : Undisclosed

    Product Type : Controlled Substance

    Upfront Cash : Inapplicable

    March 20, 2019

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Therapeutic Equivalence of Fluticasone Propionate Pressurized Metered Dose Inhaler, 110 mcg, to Flovent® HFA 110 mcg

    Details:

    Fluticasone Propionate is a Steroid drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Asthma.


    Lead Product(s): Fluticasone Propionate

    Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: Undisclosed

    Study Phase: Phase IIIProduct Type: Steroid

    Sponsor: Teva Pharmaceutical Industries

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable March 19, 2019

    blank

    08

    Actavis Inc

    Ireland
    arrow
    RDD
    Not Confirmed

    Actavis Inc

    Ireland
    arrow
    RDD
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Fluticasone Propionate

    Therapeutic Area : Pulmonary/Respiratory Diseases

    Highest Development Status : Phase III

    Partner/Sponsor/Collaborator : Teva Pharmaceutical Industries

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Therapeutic Equivalence of Fluticasone Propionate Pressurized Metered Dose Inhaler, 110 mcg, to Fl...

    Details : Fluticasone Propionate is a Steroid drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Asthma.

    Product Name : Undisclosed

    Product Type : Steroid

    Upfront Cash : Inapplicable

    March 19, 2019

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Therapeutic Equivalence of Two Formulations of Fluticasone Propionate and Salmeterol Inhalation Powder in Subjects With Asthma

    Details:

    Fluticasone Propionate is a Steroid drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Asthma.


    Lead Product(s): Fluticasone Propionate,Salmeterol Xinafoate

    Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: Undisclosed

    Study Phase: Phase IIIProduct Type: Steroid

    Sponsor: Teva Pharmaceutical Industries

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable November 28, 2018

    blank

    09

    Actavis Inc

    Ireland
    arrow
    RDD
    Not Confirmed

    Actavis Inc

    Ireland
    arrow
    RDD
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Fluticasone Propionate,Salmeterol Xinafoate

    Therapeutic Area : Pulmonary/Respiratory Diseases

    Highest Development Status : Phase III

    Partner/Sponsor/Collaborator : Teva Pharmaceutical Industries

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Therapeutic Equivalence of Two Formulations of Fluticasone Propionate and Salmeterol Inhalation Po...

    Details : Fluticasone Propionate is a Steroid drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Asthma.

    Product Name : Undisclosed

    Product Type : Steroid

    Upfront Cash : Inapplicable

    November 28, 2018

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Clinical Endpoint Study of Nepafenac 0.3% Opthalmic Suspension

    Details:

    Nepafenac is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Cataract.


    Lead Product(s): Nepafenac

    Therapeutic Area: Ophthalmology Brand Name: Undisclosed

    Study Phase: Phase IIIProduct Type: Miscellaneous

    Sponsor: Undisclosed

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable April 17, 2018

    blank

    10

    Actavis Inc

    Ireland
    arrow
    RDD
    Not Confirmed

    Actavis Inc

    Ireland
    arrow
    RDD
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Nepafenac

    Therapeutic Area : Ophthalmology

    Highest Development Status : Phase III

    Partner/Sponsor/Collaborator : Undisclosed

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Clinical Endpoint Study of Nepafenac 0.3% Opthalmic Suspension

    Details : Nepafenac is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Cataract.

    Product Name : Undisclosed

    Product Type : Miscellaneous

    Upfront Cash : Inapplicable

    April 17, 2018

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    FDF Dossiers

    read-more
    read-more

    01

    Brand Name : Serlin

    Iceland
    RDD
    Not Confirmed
    arrow

    Brand Name : Serlin

    Iceland
    arrow
    RDD
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Regulatory Info : Deregistered

    Registration Country : Sweden

    Sertraline Hydrochloride

    Medis ehff

    Dosage Form : Film Coated Tablet

    Brand Name : Serlin

    Dosage Strength : 50mg

    Packaging :

    Approval Date : 11-03-2005

    Application Number : 2.00E+13

    Regulatory Info : Deregistered

    Registration Country : Sweden

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    02

    Brand Name : Serlin

    Iceland
    RDD
    Not Confirmed
    arrow

    Brand Name : Serlin

    Iceland
    arrow
    RDD
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Regulatory Info : Deregistered

    Registration Country : Sweden

    Sertraline Hydrochloride

    Medis ehff

    Dosage Form : Film Coated Tablet

    Brand Name : Serlin

    Dosage Strength : 100mg

    Packaging :

    Approval Date : 11-03-2005

    Application Number : 2.00E+13

    Regulatory Info : Deregistered

    Registration Country : Sweden

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    03

    Brand Name : Sertrasen

    Iceland
    RDD
    Not Confirmed
    arrow

    Brand Name : Sertrasen

    Iceland
    arrow
    RDD
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Regulatory Info : Deregistered

    Registration Country : Sweden

    Sertraline Hydrochloride

    Medis ehff

    Dosage Form : Film Coated Tablet

    Brand Name : Sertrasen

    Dosage Strength : 50mg

    Packaging :

    Approval Date : 11-03-2005

    Application Number : 2.00E+13

    Regulatory Info : Deregistered

    Registration Country : Sweden

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    04

    Brand Name : Sertrasen

    Iceland
    RDD
    Not Confirmed
    arrow

    Brand Name : Sertrasen

    Iceland
    arrow
    RDD
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Regulatory Info : Deregistered

    Registration Country : Sweden

    Sertraline Hydrochloride

    Medis ehff

    Dosage Form : Film Coated Tablet

    Brand Name : Sertrasen

    Dosage Strength : 100mg

    Packaging :

    Approval Date : 11-03-2005

    Application Number : 2.00E+13

    Regulatory Info : Deregistered

    Registration Country : Sweden

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    05

    Brand Name : CAMPRAL

    U.S.A
    RDD
    Not Confirmed
    arrow

    Brand Name : CAMPRAL

    U.S.A
    arrow
    RDD
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Regulatory Info : DISCN

    Registration Country : USA

    ACAMPROSATE CALCIUM

    Forest Laboratories

    Dosage Form : TABLET, DELAYED RELEASE;...

    Brand Name : CAMPRAL

    Dosage Strength : 333MG **Federal Regist...

    Packaging :

    Approval Date : 2004-07-29

    Application Number : 21431

    Regulatory Info : DISCN

    Registration Country : USA

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    06

    Brand Name : ACARBOSE

    Ireland
    RDD
    Not Confirmed
    arrow

    Brand Name : ACARBOSE

    Ireland
    arrow
    RDD
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Regulatory Info : RX

    Registration Country : USA

    ACARBOSE

    Actavis Inc

    Dosage Form : TABLET;ORAL

    Brand Name : ACARBOSE

    Dosage Strength : 25MG

    Packaging :

    Approval Date : 2008-05-07

    Application Number : 77532

    Regulatory Info : RX

    Registration Country : USA

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    07

    Brand Name : ACARBOSE

    Ireland
    RDD
    Not Confirmed
    arrow

    Brand Name : ACARBOSE

    Ireland
    arrow
    RDD
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Regulatory Info : RX

    Registration Country : USA

    ACARBOSE

    Actavis Inc

    Dosage Form : TABLET;ORAL

    Brand Name : ACARBOSE

    Dosage Strength : 50MG

    Packaging :

    Approval Date : 2008-05-07

    Application Number : 77532

    Regulatory Info : RX

    Registration Country : USA

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    08

    Brand Name : ACARBOSE

    Ireland
    RDD
    Not Confirmed
    arrow

    Brand Name : ACARBOSE

    Ireland
    arrow
    RDD
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Regulatory Info : RX

    Registration Country : USA

    ACARBOSE

    Actavis Inc

    Dosage Form : TABLET;ORAL

    Brand Name : ACARBOSE

    Dosage Strength : 100MG

    Packaging :

    Approval Date : 2008-05-07

    Application Number : 77532

    Regulatory Info : RX

    Registration Country : USA

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    09

    Brand Name : BUTALBITAL AND ACETA...

    Ireland
    RDD
    Not Confirmed
    arrow

    Brand Name : BUTALBITAL AND ACETA...

    Ireland
    arrow
    RDD
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Regulatory Info : DISCN

    Registration Country : USA

    ACETAMINOPHEN; BUTALBITAL

    Actavis Inc

    Dosage Form : TABLET;ORAL

    Brand Name : BUTALBITAL AND ACETAMINOP...

    Dosage Strength : 325MG;50MG

    Packaging :

    Approval Date : 1984-10-19

    Application Number : 87550

    Regulatory Info : DISCN

    Registration Country : USA

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    10

    Brand Name : BANCAP

    U.S.A
    RDD
    Not Confirmed
    arrow

    Brand Name : BANCAP

    U.S.A
    arrow
    RDD
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Regulatory Info : DISCN

    Registration Country : USA

    ACETAMINOPHEN; BUTALBITAL

    Forest Laboratories

    Dosage Form : CAPSULE;ORAL

    Brand Name : BANCAP

    Dosage Strength : 325MG;50MG

    Packaging :

    Approval Date : 1986-01-16

    Application Number : 88889

    Regulatory Info : DISCN

    Registration Country : USA

    blank

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    FDA Orange Book

    read-more
    read-more

    Excipients

    Click here to find the perfect excipient manufacturers by their capabilities

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    Inspections and registrations

    Upload your audits for free, ask us

    ABOUT THIS PAGE

    Contact Actavis Inc and get a quotation

    Actavis Inc is a supplier offers 46 products (APIs, Excipients or Intermediates).

    Find Nicotine bulk with DMF, CEP offered by Actavis Inc

    Find Telmisartan bulk with DMF offered by Actavis Inc

    Find Alvimopan bulk with DMF offered by Actavis Inc

    Find Armodafinil bulk with DMF offered by Actavis Inc

    Find Cinacalcet Hydrochloride bulk with DMF offered by Actavis Inc

    Find Deferasirox bulk with DMF offered by Actavis Inc

    Find Docosanol bulk with DMF offered by Actavis Inc

    Find Enzalutamide bulk with DMF offered by Actavis Inc

    Find Ferric Citrate bulk with DMF offered by Actavis Inc

    Find Imiquimod bulk with DMF offered by Actavis Inc

    Find Iron Sucrose bulk with DMF offered by Actavis Inc

    Find Letrozole bulk with DMF offered by Actavis Inc

    Find Metoprolol Tartrate bulk offered by Actavis Inc

    Find Midodrine bulk with DMF offered by Actavis Inc

    Find Nabumetone bulk with DMF offered by Actavis Inc

    Find Nicotine bulk with DMF offered by Actavis Inc

    Find Nitrofurantoin bulk with DMF offered by Actavis Inc

    Find Oxybutynin bulk with DMF offered by Actavis Inc

    Find Oxybutynin Hydrochloride bulk with DMF offered by Actavis Inc

    Find Piroxicam bulk with JDMF offered by Actavis Inc

    Find Prilocaine bulk with DMF offered by Actavis Inc

    Find Repaglinide bulk with CEP offered by Actavis Inc

    Find Rivastigmine Tartrate bulk with DMF offered by Actavis Inc

    Find Tizanidine Hydrochloride bulk with DMF offered by Actavis Inc

    Find Trientine Hydrochloride bulk with DMF offered by Actavis Inc

    Find Varenicline Tartrate bulk with DMF offered by Actavis Inc

    Find Ambrisentan bulk offered by Actavis Inc

    Find Apixaban bulk offered by Actavis Inc

    Find CAS 50-28-2 bulk offered by Actavis Inc

    Find Cyclosporine bulk offered by Actavis Inc

    Find Doxycycline bulk offered by Actavis Inc

    Find Hydrocodone Bitartrate bulk offered by Actavis Inc

    Find Iron Dextran bulk offered by Actavis Inc

    Find Metoprolol Succinate bulk offered by Actavis Inc

    Find Moxonidine bulk offered by Actavis Inc

    Find Nicotine bulk offered by Actavis Inc

    Find Progesterone bulk offered by Actavis Inc

    Find Ramipril bulk offered by Actavis Inc

    Find Ropinirole Hydrochloride bulk offered by Actavis Inc

    Find Tazarotene bulk offered by Actavis Inc

    Find Tobramycin bulk offered by Actavis Inc

    Find Ziprasidone Hydrochloride bulk offered by Actavis Inc

    Find MANUFACTURING SITE, FACILITIES, PERSONNEL, AND GENERAL OPERAING PROCEDURES IN CORONA, CALIFORNIA. bulk offered by Actavis Inc

    Find MANUFACTURING SITE, FACILITIES , PERSONNEL, AND GENERAL OPERATING PROCEDURES IN LIBERTYVILLE, ILLINOIS. bulk offered by Actavis Inc

    Find MESTRANOL 3-METHOXY-172-ETHINYL-ESTRADIOL- MANUF PROCEDURES bulk offered by Actavis Inc

    Find Vigabatrin bulk offered by Actavis Inc

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search